Business Context and Reporting Period
Company: Alphatec Holdings, Inc. (ATEC)
Filing Type: Form 8-K (Current Report)
Date: April 19, 2023
Reporting Period: First Quarter ended March 31, 2023 (Preliminary Results)
On April 19, 2023, Alphatec Spine, Inc., a wholly-owned subsidiary of Alphatec Holdings, Inc., completed an asset acquisition of the REMI Robotic Navigation System business from Integrity Implants Inc. and Fusion Robotics, LLC. The transaction was consummated on the same date as the filing.
Key Financial Metrics
First Quarter 2023 Preliminary Results
- Total Revenue: Expected range of $108.0 million to $109.5 million (up >52% year-over-year).
- Surgical Revenue: Expected range of $93.2 million to $94.3 million (up >53% year-over-year), driven by surgical volume growth of at least 39%.
- EOS Revenue: Expected range of $14.8 million to $15.2 million.
- Cash and Cash Equivalents: Approximately $117 million as of March 31, 2023 (up from $85 million as of December 31, 2022).
- Debt Activity: Received $95.3 million in net proceeds from the Braidwell Term Loan; paid down $27.5 million on the Midcap Revolving Credit Facility.
- Net Cash Change: Cash balance increased by a net of $67.8 million due to financing activities, offset by approximately $36 million used in operating activities and capital investments.
Note: The filing does not provide specific values for net income, profit margins, or free cash flow for the quarter.
Material Changes and Transactions
- Asset Acquisition: Acquired the REMI (Robotic-Enabled Minimally Invasive) System business for cash consideration of $55,000,000. The REMI system integrates navigation and robotics into spine procedures.
- Strategic Rationale: The acquisition is expected to improve surgical predictability, reduce radiation exposure, and enhance intra-operative precision.
- Non-Compete: Sellers agreed to a three-year non-compete clause regarding the REMI Business.
- Employment: The Company agreed to offer employment to certain REMI Business employees and granted 22,741 restricted stock units (RSUs) to 18 new employees as inducement awards.
Guidance and Outlook
- Full-Year 2023 Revenue Guidance: Raised to $450 million (previously $438 million), representing approximately 28% year-over-year growth.
- Segment Guidance: Surgical revenue expected at approximately $393 million; EOS revenue expected at approximately $57 million.
- Profitability: The Company continues to expect to achieve non-GAAP adjusted EBITDA break-even for the full-year 2023.
- Reporting Schedule: Final audited Q1 2023 results are scheduled for release after market close on May 4, 2023.
Risks and Contingencies
- Integration Risks: Potential failure to realize anticipated benefits, disruption of ongoing business, and unforeseen integration expenses.
- Transaction Costs: Significant non-recurring costs (legal, advisory, filing fees) may exceed current estimates and reduce near-term benefits.
- Third-Party Contracts: Risk that customers or partners may terminate contracts or require consents that cannot be obtained.
- Personnel: Challenges in retaining key personnel from the REMI Business or attracting new talent.
- Litigation: Potential for product liability, intellectual property, or competitor claims that could divert resources.
Investor Verification Checklist
- Verify the final Q1 2023 revenue and EBITDA figures upon the May 4, 2023 earnings release to confirm preliminary estimates.
- Review the full Asset Purchase Agreement (Exhibit 2.1) for specific representations, warranties, and indemnification limitations.
- Monitor the integration progress of the REMI Business and any associated transaction costs in future quarterly reports.
- Assess the impact of the $55 million cash outlay on the Company's liquidity and debt covenants under the Braidwell Term Loan and Midcap Revolver.
- Track the retention of key REMI personnel and the vesting schedule of the 22,741 RSUs granted to new employees.